Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
OMER(NASDAQ:OMER) SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for market
Omeros Corporation Reports Second Quarter 2025 Financial Results
OMERSEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For the six months ended June 30, 2025, our net loss was $58.9 million, or $1.01 per share, compared to a net loss of $93.2 milli
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
OMERSEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conferen
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision
OMERH.C. Wainwright's Brandon Folkes initiated Omeros with a Buy.
HC Wainwright & Co. Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $9
OMERNeedham Reiterates Hold on Omerosto Hold
OMEROmeros Q1 EPS $(0.58) Misses $(0.57) Estimate
OMERExamining the Future: Omeros's Earnings Outlook
OMERD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
OMEROmeros Agrees To Acquire $80.5M Of Its Convertible Senior Notes Due 2026
OMERD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
OMERFDA Accepts Omeros' Biologics License Application For Narsoplimab In Transplant-Associated Thrombotic Microangiopathy
OMERD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
OMEROmeros Establishes Oncology Clinical Steering Committee Of Leading AML Experts From Top Cancer Centers To Advance Its OncotoX Biologics Program Targeting High-Unmet-Need Acute Myeloid Leukemia With Proprietary Engineered Molecules Designed To Deliver Canc
OMERNeedham Reiterates Hold on Omerosto Hold
OMERD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
OMEROmeros Q4 2024 GAAP EPS $(0.63) Beats $(0.82) Estimate
OMERWhat's Next: Omeros's Earnings Preview
OMERTop Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings
OMERD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
OMEROmeros Announces Phase 3 Trials For Zaltenibart In PNH With Data Expected In Q4 2026; 120 Sites In 30 Countries Activated; Focus On Intravascular And Extravascular Hemolysis With 8-Week Dosing
OMERD. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target
OMEROmeros Announces Results For Narsoplimab Expanded Access Program In TA-TMA; Results Demonstrate Marked Survival Superiority Of Narsoplimab-Treated EAP Patients, In Stand-Alone And Combined Analyses With Narsoplimab Pivotal Trial Patients, Over External Co
OMERD. Boral Capital Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $36
OMERNeedham Reiterates Hold on Omerosto Hold
OMEROmeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
OMEROmeros announces positive results from a pivotal narsoplimab trial in TA-TMA, showing significant survival benefits and advancing regulatory submissions.
Omeros' Narsoplimab Met Pivotal Trial Primary Endpoint; Given These Results, Omeros Will Resubmit To FDA As Soon As Possible Its Narsoplimab Biologics License Application For TA-TMA
OMERCantor Fitzgerald Reiterates Neutral on Omeros
OMERRodman & Renshaw Initiates Coverage On Omeros with Buy Rating, Announces Price Target of $9
OMERNeedham Reiterates Hold on Omeros
OMERNeedham Reiterates Hold on Omeros
OMER